Accord Logo

Intended for UK patients and members of the public

PIL - Losartan potassium 25, 50, 100mg Film-coated Tablets (20075): Change history

  • To update sections 4.4, 4.8 of the SmPC and sections 2, 4 of the PL to implement the signal recommendations on  Angiotensin II receptor blockers (ARBs): azilsartan; candesartan; eprosartan; irbesartan; losartan; olmesartan; telmisartan; valsartan (single ingredient and fixed dose combinations)  - Intestinal angioedema (EPITT no 20104) adopted at the 28-31 October 2024 PRAC meeting.

    • Changes: (Updated: 21 Jul 2025)

      To update sections 4.4, 4.8 of the SmPC and sections 2, 4 of the PL to implement the signal recommendations on  Angiotensin II receptor blockers (ARBs): azilsartan; candesartan; eprosartan; irbesartan; losartan; olmesartan; telmisartan; valsartan (single ingredient and fixed dose combinations)  - Intestinal angioedema (EPITT no 20104) adopted at the 28-31 October 2024 PRAC meeting.

    • Changes: (Updated: 25 Apr 2023)

      Description of update: Type IB: C.I.2.a: To update SmPC and PIL information in-line with the product information of reference product (Cozaar 12.5/25/50/100 mg film-coated tablets with Procedure reference number: NL/H/1457/001-004/DC and MAH: Merck Sharp & Dohme BV, NL) for Losartan Potassium Accord 25mg/50mg/100mg filmomhulde tabletten.

      PIL sections updated: 2, 3, 4, 6.

    • Changes: (Updated: 27 Sep 2022)

      Name corrected

    • Changes: (Updated: 27 Sep 2022)

      Initial upload

    View product information as a: